Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.
Details
Serval ID
serval:BIB_0C3E84D84ED1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative.
Journal
Ophthalmology
Working group(s)
Fundamentals of Care for Uveitis International Consensus Group
Contributor(s)
Accorinti M., Acharya N., Adan A., Agrawal R., Akkoc N., Al Ghamdi S., Al Ghamdi T., Al Saati A., Alsabaani N., Al-Shamarani M., Bachta A., Barisani-Asenbauer T., Beare N., Porto FBO, Blanco R., Yee ACS, Chandran V., Chiquet C., Chng H.H., Cimbalas A., Cimino L., Cordero-Coma M., Cristobal C., Cuevas M., Eurico da Fonseca J., de Boer J., de la Torre A., De Schryver I., Derzko-Dzulynsky L., Diaz-Valle D., Merino CED, Facsko A., Figueira L., Fonollosa A., Fortin E., Gale R., Galeazzi M., Garcia S., Garcia Ruiz de Morales J.M., Gašperšič N., Goldstein D., Guedes M., Guex-Crosier Y., Gul A., Hamam R., Haroon M., Hasegawa K., Heiligenhaus A., Hooper C., Hwang Y.S., Hwang D.K., Juanola X., Kaburaki T., Kadayifcilar S., Kempen J., Kezuka T., Kherani A., Kirsimäe M., Kotaniemi K., Kraut A., Kubicka-Trząska A., Kuffova L., Lightman S., Lim L., Lim W.K., McCluskey P., McGuire M., Mirabelli P., Miserocchi E., Misiuk-Hojło M., Muccioli C., Muñoz S., Murphy C., Murray P.I., Nagy Z., Namba K., Neri P., Nguyen Q., O'Gradaigh D., Omair M., Otsa K., Ozyazgan Y., Pablo F., Paroli M.P., Pleyer U., Poór G., Proença R., Rabinovitch T., Read R., Rebrov M., Recillas-Gispert C., Rothova A., Schwartzman S., Seve P., Sharma S., Sims J., Sohár N., Suhler E., Szántó S., Szepessy Z., Tappeiner C., Thorne J., Tugal Tutkun I., Turno-Kręcicka A., Van Calster J., van der Horst-Bruinsma I., Vidovič Valentinčič N., Vitale A., Voorduin Ramos S., Vukojevic N., Wakefield D., Willermain F., Yalcindag N., Yamamoto J.H., Yeh S., Zemaitiene R., Ziouzina O.
ISSN
1549-4713 (Electronic)
ISSN-L
0161-6420
Publication state
Published
Issued date
05/2018
Peer-reviewed
Oui
Volume
125
Number
5
Pages
757-773
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Publication Status: ppublish
Abstract
An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics.
The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents.
An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence.
In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed.
Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents.
An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence.
In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed.
Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.
Pubmed
Web of science
Open Access
Yes
Create date
15/01/2019 15:58
Last modification date
20/08/2019 12:33
Usage data
